Non-tuberculous mycobacterial infection in cystic fibrosis before and after initiation of elexacaftor/tezacaftor/ivacaftor: now is not the time to lower the guard
Ieuan Edward Shepherd Evans, Daniel Smith, Daniel Henderson, Timothy Riddles, Philip Masel, Vanessa Moore, Andrew J Burke, Rachel M Thomson, David W Reid · 2025
Read Non-tuberculous mycobacterial infection in cystic fibrosis before and after initiation of elexacaftor/tezacaftor/ivacaftor: now is not the time to lower the guard by Ieuan Edward Shepherd Evans, Daniel Smith, Daniel Henderson, Timothy Riddles, Philip Masel, Vanessa Moore, Andrew J Burke, Rachel M Thomson, David W Reid (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12742134.txt.
Description
Ieuan Edward Shepherd Evans and eight colleagues present a 2025 study on lung infections in people with cystic fibrosis. A family of germs called non-tuberculous mycobacteria has grown more common in these patients over thirty years. A powerful new drug trio, known as ETI, raised hopes it might also cut these infections, so the team tracked one Australian clinic population before and after the drugs arrived.
Over four years, the overall rate of isolating these germs barely moved. One species, Mycobacterium abscessus, held steady, while another group trended downward. The authors conclude the new therapy did not clear such infections in its first two years and screening must stay vigilant.
Catalog record
| CREATOR | Ieuan Edward Shepherd Evans, Daniel Smith, Daniel Henderson, Timothy Riddles, Philip Masel, Vanessa Moore, Andrew J Burke, Rachel M Thomson, David W Reid |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |